Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial.
Saved in:
| Title: | Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial. |
|---|---|
| Authors: | Willis BA; Work Completed While an Employee of Eli Lilly and Company. Current Affiliation: Eisai Inc., Nutley, NJ, USA., Lo AC; Work Completed While an Employee of Eli Lilly and Company., Dage JL; Work Completed While an Employee of Eli Lilly and Company. Current Affiliation: Indiana University School of Medicine, Indianapolis, IN, USA., Shcherbinin S; Eli Lilly and Company, Indianapolis, IN, USA., Chinchen L; Eli Lilly and Company, Bracknell, UK., Andersen SW; Eli Lilly and Company, Indianapolis, IN, USA., LaBell ES; Eli Lilly and Company, Indianapolis, IN, USA., Perahia DGS; Eli Lilly and Company, Bracknell, UK., Hauck PM; Eli Lilly and Company, Indianapolis, IN, USA., Lowe SL; Lilly Centre for Clinical Pharmacology, Singapore. |
| Source: | Journal of Alzheimer's disease reports [J Alzheimers Dis Rep] 2023 Sep 15; Vol. 7 (1), pp. 1015-1024. Date of Electronic Publication: 2023 Sep 15 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Publications Country of Publication: United States NLM ID: 101705500 Publication Model: eCollection Cited Medium: Internet ISSN: 2542-4823 (Electronic) Linking ISSN: 25424823 NLM ISO Abbreviation: J Alzheimers Dis Rep Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2542-4823 |
|---|---|
| DOI: | 10.3233/ADR-230012 |
